$110,000 of CINTAS CORPORATION lobbying was just disclosed, from Q4 of 2025, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Advice and counsel regarding federal regulation impacting the apparel industry. Support for defibrillation access, including H.R. 2370/S. 1024, Access to AEDs Act. Advice and counsel regarding workplace safety regulation. Advice and counsel on corporate tax reform. Advice, counsel and advocacy in support of reauthorization of US trade programs relating to Africa and Haiti."
You can find more data on corporate lobbying on Quiver Quantitative.
CTAS Congressional Stock Trading
Members of Congress have traded $CTAS stock 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $CTAS stock by members of Congress over the last 6 months:
- REPRESENTATIVE VAL T. HOYLE sold up to $15,000 on 09/23.
- REPRESENTATIVE LISA C. MCCLAIN sold up to $15,000 on 09/11.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
CTAS Insider Trading Activity
CTAS insiders have traded $CTAS stock on the open market 3 times in the past 6 months. Of those trades, 1 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $CTAS stock by insiders over the last 6 months:
- TODD M. SCHNEIDER (CEO and Director) sold 17,301 shares for an estimated $3,821,790
- RONALD W TYSOE sold 5,084 shares for an estimated $1,136,121
- MARTIN MUCCI purchased 1,200 shares for an estimated $267,060
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
CTAS Hedge Fund Activity
We have seen 593 institutional investors add shares of CTAS stock to their portfolio, and 738 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC added 1,568,421 shares (+47.4%) to their portfolio in Q3 2025, for an estimated $321,934,094
- WINSLOW CAPITAL MANAGEMENT, LLC removed 1,403,342 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $288,049,978
- FMR LLC removed 1,002,264 shares (-10.1%) from their portfolio in Q3 2025, for an estimated $205,724,708
- TWO SIGMA INVESTMENTS, LP added 998,963 shares (+5641.3%) to their portfolio in Q3 2025, for an estimated $205,047,145
- SG AMERICAS SECURITIES, LLC added 966,597 shares (+2653.0%) to their portfolio in Q4 2025, for an estimated $181,787,897
- QUBE RESEARCH & TECHNOLOGIES LTD added 850,870 shares (+135.8%) to their portfolio in Q3 2025, for an estimated $174,649,576
- VOLORIDGE INVESTMENT MANAGEMENT, LLC added 823,885 shares (+275.2%) to their portfolio in Q3 2025, for an estimated $169,110,635
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
CTAS Analyst Ratings
Wall Street analysts have issued reports on $CTAS in the last several months. We have seen 2 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- UBS issued a "Buy" rating on 12/19/2025
- Citigroup issued a "Sell" rating on 09/26/2025
- JP Morgan issued a "Overweight" rating on 09/25/2025
To track analyst ratings and price targets for CTAS, check out Quiver Quantitative's $CTAS forecast page.
CTAS Price Targets
Multiple analysts have issued price targets for $CTAS recently. We have seen 8 analysts offer price targets for $CTAS in the last 6 months, with a median target of $217.5.
Here are some recent targets:
- Leo Carrington from Citigroup set a target price of $181.0 on 12/22/2025
- Jason Haas from Wells Fargo set a target price of $242.0 on 12/19/2025
- Andrew Wittmann from Baird set a target price of $225.0 on 12/19/2025
- Ashish Sabadra from RBC Capital set a target price of $206.0 on 12/19/2025
- Joshua Chan from UBS set a target price of $235.0 on 12/19/2025
- Toni Kaplan from Morgan Stanley set a target price of $210.0 on 12/17/2025
- Connor Cerniglia from Bernstein set a target price of $200.0 on 11/12/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
